福建快3这几天是走势图 www.uclhg.icu Adlai Nortye is a science-led biopharmaceutical company dedicated to discovering, developing and commercializing new drugs in the field of oncology/immuno-oncology. Our mission is to improve patient lives by developing differentiated, innovative medicines that help people live better and longer.
We have 23 patents granted and 7 PCT published. With extensive experience in peptide a...
Adlai Nortye has received a clearance from the National Medical Products Administration (NMPA) of China for initiating the open-label, randomized, multicenter, global phase III clinical trial for pelareorep (AN1004) in combination with paclitaxel in patie
Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today released the animal model data of Buparlisib (AN2025) at the 7th ICHNO.The data suggests AN2025 could potentially be a treatment option for anti-PD-1 antibodies re
NORTH BRUNSWICK, New Jersey, -- January 3rd, 2019 -- Adlai Nortye Ltd. ("Adlai Nortye"), a global clinical-stage biopharmaceutical company today announced that it has entered into a clinical collaboration with Merck (known as MSD outside the US and Canada